PT2558079T - Composição de xarope seco de ciprofloxacina - Google Patents

Composição de xarope seco de ciprofloxacina

Info

Publication number
PT2558079T
PT2558079T PT10778730T PT10778730T PT2558079T PT 2558079 T PT2558079 T PT 2558079T PT 10778730 T PT10778730 T PT 10778730T PT 10778730 T PT10778730 T PT 10778730T PT 2558079 T PT2558079 T PT 2558079T
Authority
PT
Portugal
Prior art keywords
syrup composition
dry syrup
ciprofloxacin
ciprofloxacin dry
composition
Prior art date
Application number
PT10778730T
Other languages
English (en)
Inventor
Rajan Javeri Uma
Original Assignee
S Zhaveri Pharmakem Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S Zhaveri Pharmakem Pvt Ltd filed Critical S Zhaveri Pharmakem Pvt Ltd
Publication of PT2558079T publication Critical patent/PT2558079T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT10778730T 2010-04-12 2010-06-03 Composição de xarope seco de ciprofloxacina PT2558079T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1199MU2010 2010-04-12

Publications (1)

Publication Number Publication Date
PT2558079T true PT2558079T (pt) 2019-09-05

Family

ID=43384622

Family Applications (1)

Application Number Title Priority Date Filing Date
PT10778730T PT2558079T (pt) 2010-04-12 2010-06-03 Composição de xarope seco de ciprofloxacina

Country Status (7)

Country Link
US (1) US20130115300A1 (pt)
EP (1) EP2558079B1 (pt)
AU (1) AU2010351281B2 (pt)
CA (1) CA2802142C (pt)
NZ (1) NZ603545A (pt)
PT (1) PT2558079T (pt)
WO (1) WO2011128906A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804531A1 (en) 2019-10-11 2021-04-14 Begapinol Dr. Schmidt GmbH Granulation of topinambur

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6029682B2 (ja) 1980-07-11 1985-07-12 山之内製薬株式会社 苦味のない製剤用組成物およびその製造法
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
IN191239B (pt) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
WO2001035930A1 (en) * 1999-11-16 2001-05-25 Ranbaxy Laboratories Limited Taste masked oral compositions
CA2440069A1 (en) 2001-03-05 2002-09-12 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
MXPA04006163A (es) 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
CA2497176A1 (en) 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
WO2004087111A1 (en) * 2003-04-04 2004-10-14 Ranbaxy Laboratories Limited Oral taste masked pharmaceutical compositions
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions

Also Published As

Publication number Publication date
EP2558079A1 (en) 2013-02-20
AU2010351281A1 (en) 2012-11-29
CA2802142C (en) 2020-03-10
US20130115300A1 (en) 2013-05-09
EP2558079B1 (en) 2019-05-22
WO2011128906A1 (en) 2011-10-20
AU2010351281B2 (en) 2014-03-20
CA2802142A1 (en) 2011-10-20
NZ603545A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
GB201002983D0 (en) Nutritinal composition
GB201006200D0 (en) Composition
GB201021186D0 (en) Composition
ZA201304189B (en) Novel pharmaceutical composition
PL2579859T3 (pl) Kompozycja stała zawierająca iwabradynę
GB201006178D0 (en) Composition
GB201021269D0 (en) Composition
GB201017048D0 (en) Composition
GB201021836D0 (en) Topical Composition
ZA201206841B (en) Novel composition
GB201016970D0 (en) Composition
ZA201303199B (en) Herbicicdal composition
GB201006214D0 (en) Composition
PL2625258T3 (pl) Kompozycja do czyszczenia z polimerów
GB201019988D0 (en) Composition
GB201007531D0 (en) Composition
GB201005927D0 (en) Improved composition
GB201006204D0 (en) Composition
GB201004717D0 (en) Composition
GB201014967D0 (en) Composition
GB201010657D0 (en) Composition
GB201006182D0 (en) Composition
GB201300858D0 (en) Topical Composition
PL2534235T3 (pl) Kompozycja
GB201018130D0 (en) Composition